sorafenib,tremelimumab,durvalumab
astrazeneca,pfizer
['hcc']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty not surprising to see that occurrence of immune related adverse events (iraes) has an impact on survival for patients with hepatocellular cancer (hcc) getting the new stride regimen. best 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨